TSXV:CLAS.H - Post by User
Comment by
Belgiumboyon Apr 20, 2020 3:56pm
111 Views
Post# 30931409
RE:RE:I will
RE:RE:I will indaknownewfie wrote: Kingofstockst wrote: Never understand how some ppl here don't see anything wrong with this company, I'm invested in TBP man that company has NR all the time to update shareholders we have q&a with ceo always accessible they have 4 orphan drug designations with FDA, this team never updates us always lies stock price goes only 1 way common ppl can't be this blind... I'm invested in this but how can you not see the problem?????
<br /> <br /> <br />
Hey King. I, like you am heavily in TBP and I love what they do for us as shareholders, but I will tell you this. TBP is the exception rather than the rule. They are probably the best example that the other biotechs should aspire to be. i;m not sure how long you have been investing, not intended to be a slight, but during my time, many biotechs simply do not do NR or engage until they have something to announce. In Kaly;s case , Mr. Farrell is both the CEO and IR. So its possible that he may be preoccupied with solidifying a deal for us so his entire focus /energy is there. It is also entirely possible that we shareholders may be left holding the bag. I hope thats not the case. I want to remain cautiously optimistic that something positive may come of this. So we have three US Patents, one European Patent, Four Orphan Drug Designations, we have marketing exclusivity 7 yrs. For the US, 10 years for Europe. We were recommended for Fast Track Designation and had outstanding Phase 2 clinical results. Now is that reflected in the SP. Not right now but TBP was pushing close to $2 a share about a year ago and a bit and are now hovering around .30 but i believed in its science then and I believe in it now. Likewise. I don't think Kaly is the dead duck many want us to believe. Just trying to provide some perspective. All IMHO and I wish all good luck.
Indaknow, thanks for this beautiful post. Can I ask you a question please. I would like to hear your reaction on the idea Kalytera may be working on conditional FDA approval at this moment behind the scenes because of outstanding phase 2 results. We didn't hear anything about the research since the breakthroug in august, which may suggest something is going on.... What do you think about that?